{"nctId":"NCT02021643","briefTitle":"Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection","startDateStruct":{"date":"2013-12-10","type":"ACTUAL"},"conditions":["Chronic HCV Infection"],"count":687,"armGroups":[{"label":"Sofosbuvir+RBV+PEG 12 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: Sofosbuvir","Drug: RBV","Drug: PEG"]},{"label":"Sofosbuvir+RBV 12 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: Sofosbuvir","Drug: RBV"]},{"label":"Sofosbuvir+RBV 16 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: Sofosbuvir","Drug: RBV"]},{"label":"Sofosbuvir+RBV 24 Weeks","type":"EXPERIMENTAL","interventionNames":["Drug: Sofosbuvir","Drug: RBV"]}],"interventions":[{"name":"Sofosbuvir","otherNames":["Sovaldi®","GS-7977","PSI-7977"]},{"name":"RBV","otherNames":["Ribasphere®"]},{"name":"PEG","otherNames":["Pegasys®"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Willing and able to provide written informed consent\n* HCV RNA ≥ 10\\^4 IU/mL at screening\n* HCV treatment-naive (HCV genotype 1, 2, 3 or 6), defined as no prior exposure to any interferon (IFN), RBV, or other approved or experimental HCV-specific direct-acting antiviral agent, or HCV treatment-experienced (HCV genotype 1, 2, 3, or 6 only) with medical records that include sufficient detail of prior treatment with IFN to allow for categorization of prior response as either IFN Intolerant, non-responder, or experiences viral breakthrough or relapse\n* HCV infection documented by anti-HCV antibody test, genotyping test, or liver biopsy\n\nKey Exclusion Criteria:\n\n* Current or prior history of any clinically-significant illness (other than HCV)\n* Pregnant or nursing female or male with pregnant female partner\n* Chronic liver disease of a non-HCV etiology\n* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 is defined as HCV RNA \\< the lower limit of quantification (LLOQ; ie, \\< 25 IU/mL) 12 weeks following the last dose of study drug.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.5","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"94.2","spread":null},{"groupId":"OG004","value":"96.8","spread":null},{"groupId":"OG005","value":"95.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR24 are defined as HCV RNA \\< LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.8","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"94.2","spread":null},{"groupId":"OG004","value":"97.5","spread":null},{"groupId":"OG005","value":"97.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.5","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"90.9","spread":null},{"groupId":"OG003","value":"94.2","spread":null},{"groupId":"OG004","value":"96.8","spread":null},{"groupId":"OG005","value":"95.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-Treatment Virologic Failure","description":"Viral breakthrough was defined as HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while receiving treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Viral Relapse","description":"Viral relapse was defined as HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA \\< LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"6","spread":null},{"groupId":"OG005","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA (log10 IU/mL)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.81","spread":"0.653"},{"groupId":"OG001","value":"-4.59","spread":"0.359"},{"groupId":"OG002","value":"-4.36","spread":"0.560"},{"groupId":"OG003","value":"-4.61","spread":"0.607"},{"groupId":"OG004","value":"-4.46","spread":"0.815"},{"groupId":"OG005","value":"-4.52","spread":"0.695"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.11","spread":"0.734"},{"groupId":"OG001","value":"-4.89","spread":"0.488"},{"groupId":"OG002","value":"-4.79","spread":"0.858"},{"groupId":"OG003","value":"-5.04","spread":"0.682"},{"groupId":"OG004","value":"-4.78","spread":"1.008"},{"groupId":"OG005","value":"-4.86","spread":"0.706"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.12","spread":"0.738"},{"groupId":"OG001","value":"-4.89","spread":"0.488"},{"groupId":"OG002","value":"-4.82","spread":"0.880"},{"groupId":"OG003","value":"-5.12","spread":"0.710"},{"groupId":"OG004","value":"-4.81","spread":"1.025"},{"groupId":"OG005","value":"-4.87","spread":"0.713"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.12","spread":"0.738"},{"groupId":"OG001","value":"-4.89","spread":"0.488"},{"groupId":"OG002","value":"-4.82","spread":"0.880"},{"groupId":"OG003","value":"-5.12","spread":"0.710"},{"groupId":"OG004","value":"-4.80","spread":"1.038"},{"groupId":"OG005","value":"-4.87","spread":"0.713"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.12","spread":"0.738"},{"groupId":"OG001","value":"-4.89","spread":"0.488"},{"groupId":"OG002","value":"-4.82","spread":"0.880"},{"groupId":"OG003","value":"-5.12","spread":"0.708"},{"groupId":"OG004","value":"-4.83","spread":"0.966"},{"groupId":"OG005","value":"-4.87","spread":"0.713"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.12","spread":"0.738"},{"groupId":"OG001","value":"-4.89","spread":"0.488"},{"groupId":"OG002","value":"-4.82","spread":"0.880"},{"groupId":"OG003","value":"-5.12","spread":"0.708"},{"groupId":"OG004","value":"-4.83","spread":"0.966"},{"groupId":"OG005","value":"-4.87","spread":"0.713"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.12","spread":"0.739"},{"groupId":"OG001","value":"-4.89","spread":"0.488"},{"groupId":"OG002","value":"-4.82","spread":"0.880"},{"groupId":"OG003","value":"-5.12","spread":"0.708"},{"groupId":"OG004","value":"-4.83","spread":"0.966"},{"groupId":"OG005","value":"-4.84","spread":"0.779"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"-4.82","spread":"0.880"},{"groupId":"OG003","value":"-5.12","spread":"0.708"},{"groupId":"OG005","value":"-4.87","spread":"0.713"}]}]},{"categories":[{"measurements":[{"groupId":"OG003","value":"-5.14","spread":"0.701"},{"groupId":"OG005","value":"-4.87","spread":"0.713"}]}]},{"categories":[{"measurements":[{"groupId":"OG003","value":"-5.14","spread":"0.701"},{"groupId":"OG005","value":"-4.87","spread":"0.713"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":155},"commonTop":["Anaemia","Headache","Pyrexia","Upper respiratory tract infection","Fatigue"]}}}